Matteo Trotta - 15 Jul 2025 Form 4 Insider Report for INCYTE CORP (INCY)

Reporting relationship: EVP, GM, Dermatology US
Issuer ticker: INCY
Reported as of: 15 Jul 2025
Net transaction value: -$12,422
SEC form: 4
Accepted by SEC: 17 Jul 2025, 16:03:41 UTC
Prior SEC filing: 27 Mar 2025
Next SEC filing: 21 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Feeney, Attorney-In-Fact

Key filing fact

Matteo Trotta filed Form 4 for INCYTE CORP (INCY) on 17 Jul 2025.

Key facts

This page summarizes Matteo Trotta's Form 4 filing for INCYTE CORP (INCY).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 Jul 2025, 16:03.

Change

Previous filing in this sequence was filed on 27 Mar 2025.
Current net transaction value: -$12,422.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002015975 Primary reporting owner

Trotta Matteo

Relationship: EVP, GM, Dermatology US
Address: 1801 AUGUSTINE CUT-OFF, WILMINGTON
Signature: /s/ Elizabeth Feeney, Attorney-In-Fact
Signature date: 17 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INCY transaction

Common Stock

Tax liability

Transaction value: $12,422
Shares: -182
Change %: -1.8%
Price: $68.25
Shares after: 9,755
Date: 15 Jul 2025
Ownership: Direct
Footnotes: F1

INCY transaction

Common Stock

Award

Transaction value: $0
Shares: +5,261
Change %: +54%
Price: $0.000000
Shares after: 15,016
Date: 15 Jul 2025
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INCY transaction Derivative

Performance Shares

Award

Transaction value: $0
Shares: +13,154
Change %
Price: $0.000000
Shares after: 13,154
Date: 15 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,154
Exercise price
Footnotes: F4

INCY transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +11,841
Change %
Price: $0.000000
Shares after: 11,841
Date: 15 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,841
Exercise price: $68.25
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

Footnote F2

Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

Footnote F3

Including the July 15, 2025 grant, this includes an aggregate of 13,117 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Footnote F4

Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

Footnote F5

The July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.